Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all key financial metrics, driven by a 21% YoY surge in SUBLOCADE revenue to $253M. Revenue reached $343M, 11.5% above the $307.6M consensus, while Normalized EPS of $1.15 exceeded expectations by 24.8%. The company raised its full-year 2026 revenue guidance to $1.295B–$1.365B and announced a definitive merger agreement with Supernus, signaling a strategic transition into a broader CNS-focused biopharma leader.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Indivior Pharmaceuticals(INDV) the Revenue is 343 M (+13.58%), Beat estimate;the EBIT is 184 M (+139%), Beat estimate;the EPS is 0.98 (+600%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.34B13.58%
0.31B1.84%
+0.04B11.74%
EBITExceed expectations
0.18B138.96%
0.15B92.60%
+0.04B46.36%
EPSExceed expectations
0.98600.00%
0.775453.57%
+0.2050146.43%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf